In the 2013 San Antonio Breast Cancer Symposium, Loi and colleagues [5] reported that the presentation of TILs was associated with a higher pCR rate in the HER2-overexpression and TN phenotypes of breast tumors that underwent neoadjuvant chemotherapy (HER2-overexpression breast cancer routinely received trastuzumab treatment). This evidence concerns the gene ERBB2 and breast carcinoma.